

**MnVFC Announcement**

Date: September 26, 2023  
To: MnVFC Providers  
From: MnVFC Program  
Re: **Nirsevimab (Beyfortus) Available for Ordering**

Please route to:

- Clinical supervisor
- Medical director
- Clinic manager
- Clinic staff
- Pharmacy
- Vaccine staff

Nirsevimab (Beyfortus) will be available to order via the Minnesota Vaccine for Children (MnVFC) on Sept. 27. Even though Nirsevimab is not a vaccine, the VFC program voted to include it to the list of VFC available vaccines to help ensure that all MnVFC-eligible children will have access to it at no cost.

As you consider placing an initial order, we encourage you to be conservative in your estimates of how many doses you may administer this fall. Note that babies born between April and September will receive doses early this fall in addition to babies born during the RSV season.

- If your site uses the replacement method of vaccine management, please place a conservative order for what you expect you will use in the next month. We know implementing this may be challenging, but we appreciate your thoughtfulness when placing orders to prevent waste for this new product.

Some hospital pharmacies are already enrolled in the MnVFC program because they manage vaccines for their co-located clinics. These hospitals will be able to provide inpatient nirsevimab as part of this program but may need to adjust their practices to include monitoring inpatient unit refrigerator temperatures and documenting MnVFC eligibility in their electronic health record. Other hospital pharmacies will need to enroll in the MnVFC program directly.

The MnVFC program is interested in enrolling birthing hospitals. Information on enrollment is available at [How to Enroll in the MnVFC Program \(www.health.state.mn.us/people/immunize/hcp/mnvfc/basics.html\)](https://www.health.state.mn.us/people/immunize/hcp/mnvfc/basics.html). This may take some time, so we recommend that you ensure the primary care clinics in your area are offering nirsevimab to newborns while you work to get enrolled in the MnVFC program.

For more information, visit:

- [CDC: MMWR: Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices- United States, 2023 \(www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm\)](https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm).
- Nirsevimab (Beyfortus) package insert at [Sanofi.us: Beyfortus.pdf \(https://products.sanofi.us/beyfortus/beyfortus.pdf\)](https://products.sanofi.us/beyfortus/beyfortus.pdf)
- MnVFC Announcement at [RSV Prevention for Infants: Two New Strategies Coming this Fall \(PDF\) \(www.health.state.mn.us/people/immunize/hcp/mnvfc/ma31aug23.pdf\)](https://www.health.state.mn.us/people/immunize/hcp/mnvfc/ma31aug23.pdf).

MnVFC Program  
651-201-5522 or 1-800-657-3970  
[www.health.state.mn.us/vfc](https://www.health.state.mn.us/vfc)  
[health.mnvfc@state.mn.us](mailto:health.mnvfc@state.mn.us)